Advances and Controversies in Prostate Cancer, An Issue of Urologic Clinics

James C. Hu, William K. Oh

Description

An estimated 234,000 new cases of prostate cancer will be diagnosed in the United States this year, making it one of the most common cancers affecting American men; however, it can be a controversial disease to diagnose and treat now that there is research abounding for both “watchful waiting and aggressive treatments. Dr. Oh supplies balanced information, with articles on: Prostate Cancer: To Screen or Not To Screen?; High Intensity Focused Ultrasound: Ready for Primetime?; The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy; Primary and Salvage Prostate Cancer Cryotherapy; and The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy, to name a few. The state-of-the art information presented in this issue make is must-have for all urologists.

Sujets

• Medical
• Médecine
• Urology

Informations

• Publié par: Saunders
• Date de parution: 02 mars 2010
• Nombre de lectures: 1
• EAN13: 9781455700745
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Urologic Clinics of North America , Vol. 37, No. 1, February 2010
ISSN: 0094-0143
doi: 10.1016/S0094-0143(09)00122-0

Contributors List
Urologic Clinics of North America
Advances and Controversies in Prostate Cancer
William K. Oh
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA
Jim C. Hu
Division of Urologic Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
ISSN  0094-0143
Volume 37 • Number 1 • February 2010

Contents
Cover
Contributors List
CME Accreditation Page and Author Disclosure
Forthcoming Issues
Preface
Prostate Cancer: To Screen or Not to Screen?
Chemoprevention of Prostate Cancer
Update on Prostate Imaging
High-intensity Focused Ultrasound: Ready for Primetime
Overcoming the Learning Curve for Robotic-assisted Laparoscopic Radical Prostatectomy
The Case for Open Radical Prostatectomy
Controversies Surrounding Lymph Node Dissection for Prostate Cancer
Primary and Salvage Cryotherapy for Prostate Cancer
Current Topics in the Treatment of Prostate Cancer with Low-Dose-Rate Brachytherapy
Neoadjuvant and Adjuvant Therapies in Prostate Cancer
Novel Targeted Therapies for Prostate Cancer
Immunotherapy for Prostate Cancer: An Emerging Treatment Modality
Blood and Tissue Biomarkers in Prostate Cancer: State of the Art
Index
Urologic Clinics of North America , Vol. 37, No. 1, February 2010
ISSN: 0094-0143
doi: 10.1016/j.ucl.2010.01.001
CME Accreditation Page and Author Disclosure

Goal Statement
The goal of Urologic Clinics of North America is to keep practicing urologists and urology residents up to date with current clinical practice in urology by providing timely articles reviewing the state of the art in patient care.

Accreditation
The Urologic Clinics of North America is planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Virginia School of Medicine and Elsevier. The University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Virginia School of Medicine designates this educational activity for a maximum of 15 AMA PRA Category 1 Credits™ for each issue, 60 credits per year. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for a maximum of 15 AMA PRA Category 1 Credits™ for each issue, 60 credits per year.
Credit can be earned by reading the text material, taking the CME examination online at http://www.theclinics.com/home/cme , and completing the evaluation. After taking the test, you will be required to review any and all incorrect answers. Following completion of the test and evaluation, your credit will be awarded and you may print your certificate.

Faculty Disclosure/Conflict of Interest
The University of Virginia School of Medicine, as an ACCME accredited provider, endorses and strives to comply with the Accreditation Council for Continuing Medical Education (ACCME) Standards of Commercial Support, Commonwealth of Virginia statutes, University of Virginia policies and procedures, and associated federal and private regulations and guidelines on the need for disclosure and monitoring of proprietary and financial interests that may affect the scientific integrity and balance of content delivered in continuing medical education activities under our auspices.
The University of Virginia School of Medicine requires that all CME activities accredited through this institution be developed independently and be scientifically rigorous, balanced and objective in the presentation/discussion of its content, theories and practices.
All authors/editors participating in an accredited CME activity are expected to disclose to the readers relevant financial relationships with commercial entities occurring within the past 12 months (such as grants or research support, employee, consultant, stock holder, member of speakers bureau, etc.). The University of Virginia School of Medicine will employ appropriate mechanisms to resolve potential conflicts of interest to maintain the standards of fair and balanced education to the reader. Questions about specific strategies can be directed to the Office of Continuing Medical Education, University of Virginia School of Medicine, Charlottesville, Virginia.
The faculty and staff of the University of Virginia Office of Continuing Medical Education have no financial affiliations to disclose.
The authors/editors listed below have identified no professional or financial affiliations for themselves or their spouse/partner:
Robert Abouassaly, MD; Jalil Afnan, MD; Arie S. Belldegrun, MD, FACS; Elisa Capizzi, MSc; Fernando Carvas, BS; Kim N. Chi, MD; Wesley W. Choi, MD; David S. Finley, MD; Michelangelo Fiorentino, MD, PhD; Marcos P. Freire, MD, PhD; Kerry K. Holland (Acquisitions Editor); Jim C. Hu, MD, MPH (Guest Editor); Eric A. Klein, MD; Yin Lei, MD; Massimo Loda, MD; Stacy Loeb, MD; Robyn J. Macfarlane, MD; Edward M. Messing, MD, FACS; David C. Miller, MD, MPH; Ganesh S. Palapattu, MD, FACS; Frederic Pouliot, MD, PhD; Kyle O. Rove, MD; Edward M. Schaeffer, MD, PhD; Fabio A.B. Schutz, MD; Alex Shteynshlyuger, MD; Eric A. Singer, MD, MA; William Steers, MD (Test Author); Andrew J. Stephenson, MD; Richard G. Stock, MD; Kathryn F. Sullivan, MD; and Patrick C. Walsh, MD.
The authors/editors listed below identified the following professional or financial affiliations for themselves or their spouse/partner:
Gerald L. Andriole, MD is a consultant for Aeterna Zentaris, Amgen, EMD Serono, Ferring Pharmaceuticals, GenProbe, GlaxoSmithKline, Nema Steba, Onconome, and Veridex; is an industry funded research/investigator for Aeterna Zentaris; is on the Speakers’ Bureau for GlaxoSmithKline; and is a stockholder for Cambridge Endo, Envisioneering Medical, and Viking Medical.
E. David Crawford, MD receives compensation as a meeting participant or lecturer for Watson, Endo, GSK, Oncura, Endocare, Ferring, and Sanofi Aventis; is a consultant for Elgen; receives grant support from NIH and the University of Colorado Cancer Center; and has a family member who receives compensation from Ferring.
Charles G. Drake, MD, PhD is a consultant for Amplimmune Inc, Medarex, Inc, Dendreon, Inc, ProTox, Inc, and Sanofi Aventis, Inc; owns stock in Amplimmune Inc; and holds a patent with Medarex, Inc.
William K. Oh, MD (Guest Editor) is an industry funded research/investigator for Sanofi-Aventis and Genentech, and is on the Speakers’ Bureau for Sanofi-Aventis.
Nelson N. Stone, MD owns stock in Prologics LLC, is a consultant for Nihon MediPhysics, and is on the Advisory Committee/Board for the Prostate Cancer Education Council.
Clare M. Tempany, MD receives grant support from NIH, and is an industry funded research/investigator and consultant for Insightec Inc.
Disclosure of Discussion of Non-FDA Approved Uses for Pharmaceutical Products and/or Medical Devices.
The University of Virginia School of Medicine, as an ACCME provider, requires that all faculty presenters identify and disclose any off-label uses for pharmaceutical and medical device products. The University of Virginia School of Medicine recommends that each physician fully review all the available data on new products or procedures prior to clinical use.

To Enroll
To enroll in the Urologic Clinics of North America Continuing Medical Education program, call customer service at 1-800-654-2452 or visit us online at www.theclinics.com/home/cme . The CME program is available to subscribers for an additional fee of $195.00.
Urologic Clinics of North America , Vol. 37, No. 1, February 2010
ISSN: 0094-0143
doi: 10.1016/S0094-0143(09)00124-4

Forthcoming Issues
Urologic Clinics of North America , Vol. 37, No. 1, February 2010
ISSN: 0094-0143
doi: 10.1016/j.ucl.2009.12.001

Preface

William K. Oh, MD
Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA
E-mail address: [e-mail]
E-mail address: [e-mail]

Jim C. Hu, MD, MPH ,
Division of Urologic Surgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
E-mail address: [e-mail]
E-mail address: [e-mail]


William K. Oh, MD Guest Editor

Jim C. Hu, MD, MPH Guest Editor
Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. The past several years have been remarkable for several paradigm shifts in what we have learned about the biology of prostate cancer and how patients are being treated. Some changes represent huge shifts in technology, which have completely altered the landscape in terms of imaging, surgery, and radiation. Other findings have basically reinforced some of the facts we have known for many years, such as the key role of androgen receptor in the biology of prostate cancer.